Close

22nd Century Group (XXII) Receives Guidance from FDA on Phase III Clinical Trials for Prescription-Based Smoking Cessation Product

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/25/2024

1. META
2. CMG
3. LRCX
4. IBM
5. SPY
6. BA
7. HCP
8. SNAP
9. TMUS
10. BSX


Go back to 22nd Century Group (XXII) Receives Guidance from FDA on Phase III Clinical Trials for Prescription-Based Smoking Cessation Product

22nd Century Receives Guidance from FDA on Phase III Clinical Trials

June 22, 2017 9:55 AM EDT

Company plans to commence Phase III trials for X-22 smoking cessation product in 2018

CLARENCE, N.Y.--(BUSINESS WIRE)-- 22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced today that on June 20, 2017, the Company and its wholly owned subsidiary, Heracles Pharmaceuticals, participated in a meeting with the... More